Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
By prompting the pancreatic beta cells (-cells) to release more insulin when blood glucose levels are elevated, GLP-1s significantly lower the risk of hypoglycemia (low blood sugar) compared to traditional insulin or other types of type 2 diabetes medications
Acknowledgement The authors would like to acknowledge the Priority Academic Program Development of Jiangsu, Higher Education Institutions, Wuxi city, Jiangsu province, Peoples Republic of China
Contact us today at [email protected] to learn more about how we can meet your specific chemical needs and drive innovation in your industry
Contact your GP or diabetes specialist promptly if you experience severe persistent vomiting or diarrhoea, severe abdominal pain (particularly radiating to the back), signs of hypoglycaemia, symptoms of gallbladder problems, vision changes, or unexplained persistent nausea beyond the first few weeks
A further dimension emerged in May 2026, when the ATTAIN-MAINTAIN trial, published in Nature Medicine , found that patients who switched to orforglipron after achieving substantial weight loss on injectable GLP-1s maintained approximately 7580% of that weight reduction
